Market Report ◆ bsab-mr
Bispecific Antibody Market ReportDRAFT
BsAb-MR-2026Q3Evidence cutoff · 2026-08-19Next update · 2027-01
12Chapters · 章节
538Census trials · 普查试验
5Golden Pairs · 黄金配对
61.7%TCE share · TCE 占比
About · 简介
Intelligence-led deep-dive on the bispecific antibody market: pipeline census, TCE analysis, target pairs, autoimmune & other therapeutic areas, deals, failures and tool-demand mapping.
Executive Summary — Three Judgments
- Market growth is driven by expansion of head assets, not new targets (Top-10 assets = 72.7% of the 538-trial census).
- TCE is the largest mechanism cluster (61.7%); tool demand is shifting from commoditized CD3ε reagents to differentiated gaps (CD3δ monomer, full-length DLL3 ECD, anti-LGR5).
- Approval ≠ win — differentiation lies in earlier-line moves, generational formats and biomarkers.
Chapters · 章节
- 01Executive Summary — Three JudgmentsDRAFT
- 02Market Overview — 538-Trial Census by TADRAFT
- 03Market Size — Scenarios to 2030EDRAFT
- 04Technology Landscape — Formats Decide the Reagent StackDRAFT
- 05TCE Deep Dive — CD3ε Standard Arm and Reagent GapsDRAFT
- 06Target Pairs — Five Golden Pairs, ScoredDRAFT
- 07Autoimmune & Other TAs — Observation SectorDRAFT
- 08Clinical Pipeline — Readout Calendar and the Phase 2 SqueezeDRAFT
- 09Deals & Financing — Where the Money WentDRAFT
- 10Failures & Competition — Approval Is Not WinningDRAFT
- 11Tools & Services — Commodity 6, Differentiated 1, White Space 1DRAFT
- 12Methodology & Evidence LedgerDRAFT
Full report · 全本与下载
Read as a single page · 单页全本 → Get the PDF (email form) · 邮箱表单取 PDF
Online text is open access; the PDF download is gated by a short email form (request_type=REPORT) for attribution and the quarterly delta notice. census CSV · summary · readout calendar · TCE format shares — see bsab-market-report/data/ (Grade A, clinicaltrials.gov). Full evidence ledgers available on request. Report status: draft — under scientific review.